HaemaLogiX wins "Most Promising CAR-T Pipeline in APAC" at the Asia Pacific CGT¹ Excellence Awards 2025

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Honours
HaemaLogiX-Awarded

More Like This

HaemaLogiX Announces Appointment of Damian Clarke-Bruce as Managing Director and CEO

PR Newswire associated0

AvenCell Awarded Up to $40 Million AMED Grant to Advance Allogeneic CAR-T Program

Keymed Biosciences Announces the Latest Clinical Trial Results of CM336 Published in the New England Journal of Medicine

PR Newswire associated0

Kinomica to Present Research Abstract on a Multi-drug Biomarker Signature to Predict Best First-line Treatments for Acute Myeloid Leukemia (AML) at the 2024 ASCO Annual Meeting

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

PR Newswire associated0

AvenCell Announces First Patient Dosed in a Phase IA Study with lead product candidate AVC-201, a Novel Allogeneic CD123-Directed Switchable CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia and other CD123 Hematological Malignancies

PR Newswire associated0

Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress

XNK Therapeutics presented two posters at the NK2023 conference in Oslo